this article has been archived; content may be out of date.
#e4pMCM: the best bits from Twitter
|18th September 2014
The eyeforpharma Multichannel Marketing Summit, held at Victoria Park Plaza hotel, brought together pharma's marketing community who were all keen to learn how to enhance their current multichannel strategy. We've been following #e4pMCM to bring you the best bits of the conference, as it happened on Twitter:
Bert van Eijk @Boehringer talks #multichannel#marketing & #oncology#cancer@eyeforpharma#e4pMCM#e4pVASpic.twitter.com/BDtdB2kThu — PharmaTelevision (@PharmaTV) September 17, 2014Join it all together so that you can make decisions based on the evidence. #e4pmcmpic.twitter.com/yKwTZGWeYo — Wilf ILIFFE (@wilf66) September 17, 2014
People still think bad pharma, but there is opportunity to build trust using digital data. Context and strategy is crucial, hears #e4pMCM — Selina McKee (@PTSelinaMcKee) September 17, 2014#e4pmcm@SusSchaeffer pointing out we hide behind regulation. Eg. In SM listening — Kay Wesley (@KayWesley) September 18, 2014Chris Metzger says "Your desk is the worst place from which to view the world" - totally agree #e4pMCM — Beth Moore (@BethLMoore) September 18, 2014Ben from @bmorecreative24 discussing (and wearing!) how google glass & wearable tech will change healthcare #e4pMCMpic.twitter.com/ddqiTU7ksY — Polly Lutter (@polwar13) September 17, 2014Interesting that GPs are looking for similar information/capabilities in different places. Some inefficiencies being discussed. #e4pMCM — Gareth Dabbs (@garethdabbs) September 18, 2014A key way patients make decisions about their therapies is by talking to each other #e4pMCM — ThePharmaLetter (@ThePharmaLetter) September 18, 2014"If it's not improving the experience why are we doing it?" says @PharmaCXM. Great question #e4pMCM — Rebecca Belton (@beckybelton) September 17, 2014GP says 'I'm a human being not a segment'-be open & transparent,allow us to be professionals & balance risks & benefits #e4pMCM — Julie O'Donnell (@julieodonn) September 18, 2014Best session yet - 2 UK GPs talking about value of reps, digital, MCM: "focus on confidence transfer - not how great your drug is" #e4pMCM — Polly Lutter (@polwar13) September 18, 2014#e4pmcm iPad detailing cannot replace experience and knowledge from reps - just being there to navigate the slides is not the way forward. — Chris Wade (@wadoinlondon) September 18, 2014'Why can't I speak to the person who knows most about the medication' very true. #e4pMCM — Gareth Dabbs (@garethdabbs) September 18, 2014Another wow experience here at #e4pMCM: pfizer showing results from remote rep project! Go figure!! pic.twitter.com/8Lg6dMPpBX — Susanne Schäffer (@SusSchaeffer) September 17, 2014Patient panel: it doesn't matter thru what channel we communicate - we have try the patients shoes #e4pMCM — Nataliya Andreychuk (@nataliaand) September 18, 2014There's no denying that the main topic for discussion at the conference was around patient-centricity and the importance of finding out what is it that your customer needs, before designing a product or service for them.
If you’d like to discuss how we can help you meet your own challenges, call us on +44 203 328 1840 or contact us via email at hello@bluelatitude.com.
Empowered patients: shaking the foundations of healthcare
|16th August 2019
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to make a more accurate treatment decision. Here we discuss the barriers, opportunities and potential outcomes of the precision medicine era in healthcare.
A uniquely English genomic medicine service
|26th July 2019
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist and Director of Public Health at Genomics England, to find out how the NHS is achieving this goal.
Diagnosing the lag in neuropsychiatric treatments
|16th July 2019
The number of mental health research programmes in larger drug firms has shrunk by 70% in the past decade. Blue Latitude Health Senior Associate Consultant Sana Rahim explores this drop in investment and explains why developing a market-orientated model is vital for making progress.